2 weeks Ago By ABMN Staff
Shares of Novavax, Inc. ( NASDAQ:NVAX – Get Free Report ) traded up 6.7% during mid-day trading on Friday .
The stock traded as high as $13.03 and last traded at $12.96.
2,902,919 shares changed hands during mid-day trading, a decline of 72% from the average session volume of 10,324,533 shares. The stock had previously closed at $12.15.
Analysts Set New Price Targets A number of equities analysts have recently commented on the stock. JPMorgan Chase & Co. increased their price objective on shares of Novavax from $8.
00 to $9.00 and gave the stock an “underweight” rating in a research note on Monday, August 12th. B.
Riley restated a “buy” rating and issued a $23.00 price target (down from $25.00) on shares of Novavax in a research note on Monday, August 12th.
Finally, Bank of America upped their price objective on Novavax from $12.00 to $18.00 and gave the stock a “neutral” rating in a research note on Friday, June 14th.
One analyst has rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the stock. According to data from MarketBeat, Novavax currently has an average rating of “Hold” and an average target price of $15.80.
Check Out Our Latest Stock Report on Novavax Novavax Price Performance Novavax ( NASDAQ:NVAX – Get Free Report ) last posted its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported $0.99 earnings per share for the quarter, missing analysts’ consensus estimates of $1.
82 by ($0.83). The company had revenue of $415.
50 million during the quarter, compared to analyst estimates of $458.57 million. During the same quarter in the previous year, the business posted $0.
58 EPS. The company’s revenue for the quarter was down 2.1% compared to the same quarter last year.
As a group, equities analysts anticipate that Novavax, Inc. will post -1.04 earnings per share for the current fiscal year.
Institutional Trading of Novavax Hedge funds and other institutional investors have recently modified their holdings of the stock. Banque Cantonale Vaudoise raised its holdings in Novavax by 500.0% in the 2nd quarter.
Banque Cantonale Vaudoise now owns 3,000 shares of the biopharmaceutical company’s stock valued at $38,000 after acquiring an additional 2,500 shares during the period. Amalgamated Bank lifted its holdings in Novavax by 26.9% during the 2nd quarter.
Amalgamated Bank now owns 4,887 shares of the biopharmaceutical company’s stock worth $62,000 after purchasing an additional 1,036 shares during the last quarter. Swedbank AB acquired a new stake in Novavax during the 1st quarter worth approximately $26,000. Signaturefd LLC boosted its stake in Novavax by 214.
5% in the 2nd quarter. Signaturefd LLC now owns 5,680 shares of the biopharmaceutical company’s stock valued at $72,000 after purchasing an additional 3,874 shares during the period. Finally, Herr Investment Group LLC acquired a new stake in shares of Novavax during the first quarter worth $48,000.
Institutional investors own 53.04% of the company’s stock. Novavax Company Profile ( Get Free Report ) Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases.
It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. See Also Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter .
.
